-
公开(公告)号：US20240002494A1
公开(公告)日：2024-01-04
申请号：US18210885
申请日：2023-06-16
Applicant: Janssen Biotech, Inc.
Inventor： Jewel Johanns , Katherine Li , Colleen Marano , Richard Strauss , Hongyan Zhang , Christopher O'Brien , Omoniyi Adedokun , Kimberly Shields-Tuttle
CPC classification number: C07K16/244 , A61P1/04 , A61K2039/545
Abstract: Described are methods and compositions for clinical proven safe and effective treatment of ulcerative colitis, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.
-
公开(公告)号：US10961307B2
公开(公告)日：2021-03-30
申请号：US16580509
申请日：2019-09-24
Applicant: Janssen Biotech, Inc.
Inventor： Jewel Johanns , Katherine Li , Colleen Marano , Richard Strauss , Hongyan Zhang , Christopher O'Brien , Omoniyi Adedokun , Kimberly Shields-Tuttle
Abstract: Described are methods and compositions for clinical proven safe and effective treatment of ulcerative colitis, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.
-
公开(公告)号：US20200095315A1
公开(公告)日：2020-03-26
申请号：US16580509
申请日：2019-09-24
Applicant: Janssen Biotech, Inc.
Inventor： Jewel Johans , Katherine Li , Colleen Marano , Richard Strauss , Hongyan Zhang , Christopher O'Brien , Omoniyi Adedokun , Kimberly Shields-Tuttle
Abstract: Described are methods and compositions for clinical proven safe and effective treatment of ulcerative colitis, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.
-
公开(公告)号：US20210347880A1
公开(公告)日：2021-11-11
申请号：US17308302
申请日：2021-05-05
Applicant: Janssen Biotech, Inc.
Inventor： Omoniyi Adedokun , Daphne Chan , Yang Chen , Philippe Szapary
Abstract: A method of treating Crohn's disease in a patient administers an IL-23 specific antibody, e.g., guselkumab, at an initial intravenous dose and subsequent subcutaneous doses in order for the patient to respond to the antibody and meet one or more of the clinical endpoints.
-
公开(公告)号：US20210253690A1
公开(公告)日：2021-08-19
申请号：US17175129
申请日：2021-02-12
Applicant: Janssen Biotech, Inc.
Inventor： Jewel Johanns , Katherine Li , Colleen Marano , Richard Strauss , Hongyan Zhang , Christopher O'Brien , Omoniyi Adedokun , Kimberly Shields-Tuttle
Abstract: Described are methods and compositions for clinical proven safe and effective treatment of ulcerative colitis, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.
-
Patent Agency Ranking
公开(公告)号：US20210115129A1
公开(公告)日：2021-04-22
申请号：US17072298
申请日：2020-10-16
Applicant: Janssen Biotech, Inc.
Inventor： Jewel Johanns , Katherine Li , Colleen Marano , Richard Strauss , Hongyan Zhang , Christopher O'Brien , Omoniyi Adedokun , Kimberly Shields-Tuttle
Abstract: Described are methods and compositions for clinically proven safe and effective treatment of ulcerative colitis according to the product label described herein, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.
-
公开(公告)号：US12138295B2
公开(公告)日：2024-11-12
申请号：US17212424
申请日：2021-03-25
Applicant: Janssen Biotech, Inc.
Inventor： Omoniyi Adedokun , Daphne Chan , Yang Chen , Philippe Szapary
Abstract: A method of treating Crohn's disease in a patient administers an IL-23 specific antibody, e.g., guselkumab, at an initial intravenous dose and subsequence subcutaneous doses.
-
公开(公告)号：US20240368265A1
公开(公告)日：2024-11-07
申请号：US18765663
申请日：2024-07-08
Applicant: Janssen Biotech, Inc.
Inventor： Omoniyi Adedokun , Daphne Chan , Yang Chen , Philippe Szapary
Abstract: A method of treating Crohn's disease in a patient administers an IL-23 specific antibody, e.g., guselkumab, at an initial intravenous dose and subsequent subcutaneous doses in order for the patient to respond to the antibody and meet one or more of the clinical endpoints.
-
公开(公告)号：US20240182557A1
公开(公告)日：2024-06-06
申请号：US18383310
申请日：2023-10-24
Applicant: Janssen Biotech, Inc.
Inventor： Jewel Johanns , Katherine Li , Colleen Marano , Richard Strauss , Hongyan Zhang , Christopher O'Brien , Omoniyi Adedokun , Kimberly Shields-Tuttle
CPC classification number: C07K16/244 , A61K9/0019 , A61K9/08 , A61K39/00 , A61K47/183 , A61K47/22 , A61K47/26 , A61P1/04 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/31 , C07K2317/565
Abstract: Described are methods and compositions for clinical proven safe and effective treatment of ulcerative colitis, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.
-
公开(公告)号：US20190269757A1
公开(公告)日：2019-09-05
申请号：US16291310
申请日：2019-03-04
Applicant: Janssen Biotech, Inc.
Inventor： Omoniyi Adedokun , Daphne Chan , Yang Chen , Philippe Szapary
Abstract: A method of treating Crohn's disease in a patient administers an IL-23 specific antibody, e.g., guselkumab, at an initial intravenous dose and subsequence subcutaneous doses.
-
-
-
-
-
-
-
-
-
Search Results
16
records
(took 0.019 seconds)
